HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Pharmaceutical Industries Ltd.

https://www.tevapharm.com/

Latest From Teva Pharmaceutical Industries Ltd.

Inhaler Changes For Environmental Reasons Worry Generic Sponsors, Prompt Call For FDA Research

ANDA sponsors say eliminating the HFC propellant, while important to help address climate change, could upend the generic market without guidance from the US FDA.

Generic Drugs Combination Products

UK Lucentis Biosimilar Nod Offers Teva Potential First-Mover Advantage

Teva is gearing up to introduce the Ongavia ranibizumab biosimilar in the UK, following an approval by the local regulator ahead of its European counterpart. The development means the Israeli firm and partners Bioeq and Formycon could secure a global first launch of a rival to Lucentis, ahead of expected imminent launches by Samsung Bioepis of its Byooviz version in the US and Europe.

Biosimilars Approvals

UK Lucentis Biosimilar Nod Offers Teva Potential First-Mover Advantage

Teva is gearing up to introduce the Ongavia ranibizumab biosimilar in the UK, following an approval by the local regulator ahead of its European counterpart. The development means the Israeli firm and partners Bioeq and Formycon could secure a global first launch of a rival to Lucentis, ahead of expected imminent launches by Samsung Bioepis of its Byooviz version in the US and Europe.

Biosimilars Approvals

Teva: Payers Hold The Cards On Material 2023 Adalimumab Opportunity

Fresh from partner Alvotech resolving patent litigation in the US for its proposed Humira biosimilar, Teva management has detailed the firm’s expectations around the product and the crucial issue of supply.

Biosimilars Reimbursement
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • ABIC Marketing Limited
    • AbZ-Pharma
    • Auspex Pharmaceuticals, Inc. (Imphar AG)
    • Barr Pharmaceuticals
    • Bentley Pharmaceuticals
    • BioGeneriX AG
    • BioAssets Development Corporation
    • Cephalon, Inc. (Arana Therapeutics (Peptech and EvoGenix)
    • Ception Therapeutics
    • ChemGenex Pharmaceuticals Limited
    • CIMA Labs
    • Gemin X Pharmaceuticals
    • CT Arzneimittel GmbH
    • Gecko Health Innovations
    • IVAX Corporation
    • Labrys Biologics
    • Mepha
    • MicroDose Therapeutx Inc.
    • Neose Technologies, Inc.
    • NuPathe, Inc.
    • PLIVA HRVATSKA d.o.o.
    • ratiopharm Group
    • Sicor Biotech
    • Representaciones e Investigaciones Médicas, S.A. de C.V.
    • Taiyo Pharmaceutical Industry Co. Ltd.
    • Teva Branded Pharmaceutical Products, R&D Inc.
    • Teva Women's Health, Inc.
    • Actavis Generics
    • Anda, Inc.
    • Uteron Pharma S.P.R.L.
    • Teva Takeda Yakuhin Ltd.
    • Teva Takeda Pharma Ltd.
    • Teva Neuroscience, Inc.
    • Teva Pharmaceuticals USA, Inc.
    • Zeneus Pharma
UsernamePublicRestriction

Register